Lifting FDA hold on heart drug trial top 2023 priority for Verve - RBC
13/01/2023 23:09
** Brokerage RBC Capital Markets says Verve Therapeutics'
VERV.O key priority in 2023 is to lift the FDA's clinical hold
from its heart drug trial
** Says VERV is working on responding to the FDA's questions
related to additional data on potency, off-target editing,
transgenerational risk of its experimental therapy, VERVE-101
** Co is testing its gene editing therapy, VERVE-101, as a
potential treatment for a subtype of a genetic heart disease
called atherosclerotic cardiovascular disease (ASCVD)
** Based on RBC's interactions with VERV, co has an
experimental plan in place, but timelines are yet to be decided
** RBC says VERV's priorities also include to present
clinical data from outside U.S. early-stage trial for therapy
** Adds data from trial, which is ongoing in both New
Zealand and United Kingdom, is on track for H2 2023 and will
include a minimum of 12 patients' data
** 7 of 10 brokerages rate the stock "buy" or higher, 2 rate
it "hold" and 1 rates it "sell"; their median PT is $39
** As of last close, VERV has fallen ~26% in past 12 months
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))